

Index

- Adenosine monophosphate
 - (AMP)-dependent protein kinase activity, inhibition of mTOR by, 123
- Adenosine triphosphate (ATP), fall in levels of, as a mTOR regulator, 109
- Adipocytes, *see also* Leptin
 - and connective tissue metabolism in osteoarthritis, 25
 - decreased maturation of, in bone marrow stromal cells in osteoarthritic patients, 26
- A disintegrin-like and metalloprotease domain with thrombospondin type I motifs (ADAMTS), *see also* Aggrecanase
- ADAMTS-4
 - induction transforming growth factor- β , 50
 - mediation of aggrecan degradation by, 115
 - role in collagen degradation, 53
 - splitting of decorin by, 87
- ADAMTS-5
 - increase in expression of, after injury to cartilage, 167
 - mediation of aggrecan degradation by, 114
 - susceptibility to osteoarthritis associated with, 43
 - cleavage of procollagen by, 84
 - effect on charge density and osmotic pressure, 124–125
 - substrates for, 87, 89
- Advanced glycation end products (AGE)
 - accumulation in aging cartilage, 53
 - receptor for, chondrocyte expression of, 76
- Affected sibling pair (ASP), in a linkage scan study using hip and knee replacement patients, 134
- Age
 - and apoptosis of articular chondrocytes, 118
 - and growth factor expression, 50
 - and hip and knee replacement suitability, 14
 - and incidence of osteoarthritis, 2, 165
 - and osteoarthritic development in guinea pigs, 157–158
 - and proteolysis of the C-terminal part of aggrecan, 83
 - as a risk factor in osteoarthritis, 26
- Aggrecan
 - aggregates of, 82–83
 - attack on, in cartilage degradation, 86–87, 113–114
 - in cartilage, 8
 - function of, 123
 - turnover in osteoarthritis, 99
 - in a cartilage matrix, 82
 - in collagen, 2, 27
 - compressive stiffness of cartilage matrix due to interactions of, 98
 - gene for, on chromosome, 29, 134
 - in the interterritorial cartilage matrix, 41–42
 - loss of, in osteoarthritis, 165
 - release of, by interleukin-6, 87–88
- Aggrecanase; *see also* A disintegrin-like and metalloprotease domain with thrombospondin type I motifs (ADAMTS)
 - biglycan cleavage by, 90
 - role in aggrecan release, 88
- Alkaline phosphatase
 - increase in activity in the osteoarthritic hip, 23
 - levels in osteoblasts, 25
 - levels in the upper zone of cartilage in osteoarthritis, 118
- Alternative therapies, for pain relief in osteoarthritis, 181
- American College of Rheumatology, 1
- Anabolic cytokines, roles in synthesis of cartilage matrix components, 72
- Anabolic mediators, of cartilage healing, 97
- Anabolism
 - cartilage, vii–viii, 52
 - and disease progression, 67, 183
 - in a mouse model, locations of activity, 156
- Anaerobic glycolysis, in chondrocytes, 111, 116, 123
- Anakinra, rheumatoid arthritis treatment with, 187–188
- Analgesics, 13, 181, 182, 189
 - for managing pain in osteoarthritis, 181–182

- Angiogenesis
 by interleukin-17 induction of vascular endothelial growth factor, 49
 effect of bisphosphonates on, 183
 in subchondral bone, in response to hypoxia, 20–21
- Animal models
 baboon, study of nutrients for cartilage, 28
 bovine, effects of impact loads on cartilage-bone cylinders, 170
 dog
 effects of impact loads on cartilage-bone cylinders, 170
 for osteoarthritis, 150–151
 for subchondral bone remodeling and resorption in osteoarthritis, 29
 for treating osteoarthritis with cathepsin K inhibitors, 190
 guinea pig, of spontaneous arthritis, 157–158
 mouse
 ADAMTS-deficient, susceptibility to osteoarthritis, 43
 biglycan/fibromodulin deficient, 2
 developmental defects in cartilage matrix proteins, 45
 evaluation of prlnacaskan using, 186
 interleukin-1 knockout, protection against surgically induced osteoarthritis, 48
 interleukin-6 knockout, incidence of osteoarthritis on aging, 48
 lacking alpha 1 (IX) collagen, noninflammatory degenerative joint disease in, 8
 of osteoarthritis, 45, 153–155
 osteocalcin knockout, mineralization pattern in, 22
 study of aggrecan degradation, 89
 transgenic or knockout, and susceptibility to osteoarthritis, 48
 transgenic or knockout, with disrupted cytokine signaling, 46
 murine, osteophyte induction in, 67, 70
 for osteoarthritis, 161, 181
 with disrupted cytokine expression or signaling, 48
 doxycycline evaluation, 189
 effects of bisphosphonates, 183
 overview, vii
 trauma induced, 10, 12
 treatment with matrix metalloproteinase inhibitors, 187, 188
 pig patella, effects of impact loads on cartilage-bone cylinders, 170
 rat meniscal tear, effect of fibroblast growth factor-18 on cartilage repair in, 51, 156
 for regulation of chondrocyte apoptosis with caspase-3 inhibitor, 125
 steers, gene upregulation in explanted cartilage after stress loading, 171
 steer shoulder joints, effects of mechanical injury on cell death, 172
 TUNEL-positive cells in osteoarthritis, 118, 120, 170
 use of interleukin-1 β converting enzyme inhibitor to manage osteoarthritis, 72
- Ankle joints, measuring cartilage lesions in, 101
- Annexins
 II and V, in the upper zone of cartilage in osteoarthritis, 112
 V, as a collagen type II receptor, 43
- Anterior cruciate ligament (ACL), injuries to, and relative risk of osteoarthritis, 165
- Anterior cruciate ligament (ACLTX) transection models
 dog model of osteoarthritis, 150–151
 rat model of osteoarthritis, 153
- Anterior cruciate ligament transection (ACLTX) models, for studying degenerative osteoarthritis, 183
- Antiangiogenic factors, loss from cartilage in osteoarthritis, 6
- Apoptosis
 of chondrocytes
 osteoarthritic, 115–119
 as a target in drug development for osteoarthritis, 124
 triggering by direct loading injury, 169
 comparison with autophagy, 122
 comparison with necrosis, 168–169
 defined, 2, 41
 evidence for, in osteoarthritic cartilage, 118–119
 regulation of, in osteoarthritic chondrocytes, 119, 121
- Apoptosis inducing factor (AIF), release by the mitochondrial inner transmembrane transition, 118
- Apoptosome complex, defined, 118
- Arthrodesis, 13–14
- Arthroplasty, for symptom relief, undesired effects of, 182, 186, 188, 190
- Arthroscopy, diagnostic and therapeutic, 3, 5, 14
- Articular cartilage
 adult, the chondrocyte in, 41, 42

- bovine, effects of impact loads on cartilage-bone cylinders, 169
- collagen and proteoglycan of, 97
- composition and structure of, 110
- microscopic changes in, 8
- nutrition of, and the role of hypoxia, 20
- role in initiation and progression of osteoarthritis, 5, 41, 53, 174
- and subchondral bone, crosstalk between, 29, 41, 157, 159
- Articular chondrocytes
 - comparison with growth plate cells, parallels and differences, 110
 - enzymes originating in, 10
 - fibroblast growth factor-2 as a mitogen for, 51
 - gene expression changes responsible for osteoarthritis, 141
- Articular gelling, stiffness due to, 2
- Asporin
 - gene for
 - association with hip and knee osteoarthritis, 139
 - and cartilage matrix maintenance, 2
 - inhibition of cartilage anabolism by, 52
 - N-terminal domain of, variation in normal and osteoarthritic tissue, 86
- Association scans, studies using, to identify susceptibility genes for osteoarthritis, 138–139
- Autoimmune responses, to cartilage breakdown, contributing to osteoarthritis pathology, 72
- Autophagosomes, formation of, 123
- Autophagy
 - of chondrocytes
 - in osteoarthritic cartilage, 122–123
 - regulation of, 119
 - as a response to bone vascularization and induction of osteoarthritis, 122
- Basic fibroblast growth factor (bFGF), *see* Fibroblast growth factor (FGF), –2, binding to heparan sulfate chains
- Bax, proapoptotic protein, study of, in osteoarthritis, 119
- Bcl-2 antiapoptotic protein, role in osteoarthritis, 118–119
- Biglycan
 - activation of macrophages by, in articular cartilage, 69
 - fragmentation of, 89, 90, 91
 - three-dimensional structure of, 86
- Biomarkers, of joint injury and osteoarthritis, proteomic approaches, 174, 187
- Biomechanical aspects, of joint injury and osteoarthritis, 165
- Biomechanical processes
 - in osteoarthritis, 23–24
 - trauma inducing osteoarthritis, 42
- Biosynthetic phase, of osteoarthritis, 111
- Bisphosphonates
 - effects on osteoclasts, 185
 - labeled, elevated bone cell activity in severe osteoarthritis, 24
 - as matrix metalloproteinase inhibitors, 188
- Blood flow to subchondral bone, 20
- Body mass index (BMI), high, association with osteoarthritis, 19
- Bone
 - abnormal growth of, as a risk factor for osteoarthritis, 26
 - changes in osteoarthritis, 21
 - interaction with cartilage, in osteoarthritis, 27–29
 - mass at affected sites, 19
 - role in development of osteoarthritis, 19–30
 - overview, v
 - turnover rate, and osteoarthritis progression, 26
 - vascularization of, and induction of the osteoarthritic state, 122
- Bone marrow, edema of, in osteoarthritis, 26
- Bone mineral density (BMD)
 - change in, in osteoarthritis, 122
 - decrease in knee osteoarthritis, 183
 - increase in osteoarthritis, 21, 26
 - targeting genes that encode, 132
- Bone morphogenetic proteins (BMPs)
 - 2
 - anabolic activity of, 101, 102
 - effect of, on expression of collagen type IIB, 20
 - induction of, 51
 - induction of, in cartilage explants, 169, 170, 171, 172
 - by tumor necrosis factor- α and interleukin-2 β , 102
 - role in joint development and tissue repair, 51–53
 - signal transduction by, 47, 117, 139, 171
 - disruption resulting in cartilage degeneration, 54
- Bone remodeling, growth factors associated with, in osteoarthritic bone, 27
- Bone resorption
 - increase in, and bone mineral density, 24, 26
 - protection against, by cannabinoid receptors, 25
- Bone scans, in pain, to eliminate alternates to osteoarthritis, 5

- Bone scintigraphic signal, to evaluate progression of osteoarthritis, 21
- Bone tissue, role in osteoarthritis progression, 21, 22, 26–28
- Boyle–Van’t Hoff equation, describing osmotic responses of chondrocytes, 115
- British Study of Risedronate in Structure and Symptom of Knee Osteoarthritis (BRISK), 184
- Calcitonin, intranasal, for treating hypercalcemia and postmenopausal osteoporosis, 185
- Calcium ion (Ca^{2+}), sources of, and apoptosis, 120–121
- Calmodulin 1, gene for, and cartilage matrix maintenance, 2
- Calpains
 - calcium ion activation of, leading to cell death, 120–121
 - role in tissue breakdown, 87
- Cancellous bone, of the osteoarthritic hip, matrix metalloprotein-2 activity in, 22, 23
- Cancer, methylation changes in regulatory regions of gene promoters involved in, 141
- Candidate genes, case-control cohort studies using, 132, 137
- Cannabinoid receptors, antagonists of, protection against bone resorption by, 25
- Capsular ligaments, destruction and distortion of, 3
- Carbohydrate metabolism, effect of cytosol “shape” on, 117
- Cardiovascular disease risk factors, correlation with osteoarthritis risk factors, 23
- Cartilage; *see also* Articular cartilage
 - anabolic mediators in healing of, 97
 - biomechanics of, 166
 - calcified, interaction with bone, 52, 53
 - changes in, during experimental osteoarthritis, 69
 - cytokines, growth factors, and bone-derived factors in, 41, 45, 47, 48, 72
 - degradation of
 - growth factors affecting, 28
 - after medial meniscal tear-induced osteoarthritis in guinea pigs, 157–158
 - progression of, 12
 - sequence of events in, 87
 - genes involved in catabolism of, expression in osteoarthritic chondrocytes, 142
 - injured, co-culture with joint capsule tissue in vitro, 174
 - loss of, from weight bearing areas, 3
 - metacarpophalangeal, changes in transcription after mechanical injury, 171
 - microscopic changes in with osteoarthritis, 8
 - osteoarthritic, evidence for apoptosis in, 116–117
 - and subchondral bone, crosstalk between, 28, 29
 - synovial receptors for components of, 74
 - in vitro models of acute mechanical injury to, 167, 169
 - damage to matrix and cells, 169
- Cartilage cell, hypertrophy of, overview
- Cartilage matrix
 - degradation of, 87, 88
 - organization and regulation of assembly of, 82
 - synthesis of, in osteoarthritis, 41–43
- Cartilage oligomeric matrix protein (COMP)
 - catalytic role in fibrillogenesis, 85
 - fragmentation of, 89, 90
 - gene for, on chromosome, 26, 132
 - increase in fragments, after joint injury, 166
 - interaction with collagenous domains, 84
- Caspases
 - 1, inhibitor to treat osteoarthritis, 185
 - 3, inhibitor to regulate chondrocyte apoptosis, 125
 - activation in apoptotic chondrocytes, 117–118
 - downstream of the intrinsic and extrinsic apoptotic pathways, 115
- Catabolism
 - cartilage, 49
 - genes involved in, 142–144
 - cytokines involved in, from the osteoarthritic synovium, 72
 - enzymes involved in, synovial expression of, 87
 - induction by interleukin- 1β , reversal by bone morphogenetic protein-7, 50
- Cathepsin K
 - inhibitors of, for treating osteoarthritis, 190
 - role in bone collagen breakdown, 91
- CD44 hyaluronan receptor, 74
- CD44 transmembrane glycoprotein, in osteoarthritis chondrocytes, 76
- Cell death in osteoarthritis, 12; *see also* Apoptosis; Autophagy

- Cellular tensegrity, theory of, 114
- Charnley hip, success of, 14
- Chemokines, expression by chondrocytes, 47, 49
- Chingford study, measurement of bone resorption in, 21
- Chondral changes, grading, 5
- Chondroadherin, linkage between extracellular matrix and chondrocytes using, 86
- Chondrocytes
- anabolism in osteoarthritic, v, 97
 - “arthritic” phenotype of, 10
 - biosynthesis of, effects of mechanical injury on, 170–171
 - characteristics in osteoarthritis, 122
 - death of, in stage 3 osteoarthritis, 12
 - decreased maturation in bone marrow stromal cells, 22, 27
 - dedifferentiation of, 20
 - measures of, 173, 188
 - in osteoarthritis, 20–21
 - differentiation of, role of osteoblasts in, 29, 42
 - DNA hypermethylation and silencing of genes of, 140
 - expression of collagen type IIA in osteoarthritis, 20
 - growth-plate, marker for hypertrophy of, 21
 - hypertrophy and apoptosis of, at the cartilage-bone interface, 109–125
 - inflammatory mediators produced by, in initial stages of osteoarthritis, 41
 - interleukin-1 as a regulator of the function of, 46
 - osteoarthritic changes in
 - in mechanoresponsiveness, 171–172
 - metabolic, 97–98
 - role in matrix degradation, 7–10
 - stage of changes in, and severity of osteoarthritis, 8
- Chondrodysplasias, osteoarthritis associated with, 2
- Chondrogenesis, stimulation by transforming growth factor- β , 68
- Chondroitin sulfate (CS) chains, component of aggrecans, 82–86
- Chondroptosis, defined, 12
- Chordin, appearance in osteoarthritis cartilage, 52
- Chromosomes
- 1p21.1, *COL11A1* gene of, 132
 - 2, osteoarthritis susceptibility loci, 136–137
 - 2q
 - interleukin-1 family genes on, 133
 - osteoarthritis susceptibility locus, 133
 - 2q13, interleukin-1 β gene locus, 133
 - 4q, osteoarthritis susceptibility locus, 133
 - 6
 - linkage to hip osteoarthritis in female sibling pairs, 136
 - osteoarthritis susceptibility locus, 138
 - 6p21.32, *COL11A2* gene of, 132
 - 6q25.1, estrogen receptor α gene locus, 132
 - 9q, asporin gene on, association with osteoarthritis, 137
 - 10q26.2, *ADAM12* of, 144
 - 11, association with hand osteoarthritis, 138
 - 11q, osteoarthritis susceptibility locus, 26, 132
 - 12q13.11
 - COL2A1* gene of, 132
 - vitamin D receptor gene locus, 132
 - 15q16, *AGC1* gene of, 132, 132
 - 16, osteoarthritis susceptibility locus, 138
 - 19p13.11, *COMP* gene of, 132
 - 19q13, transforming growth factor- β 1 locus, 133
- Cilium, of chondrocytes, 111
- C-Jun N-terminal kinases (JNKs), 47
- Cleavage sites, of aggrecan, chondroitin sulfate-rich domain, 88
- Clinical findings
- in joint loading damage, 166
 - in osteoarthritis, 10–12
- Clinical trials, of bisphosphonates in osteoarthritis, 182–184
- COL2A1
- downregulation in cultured chondrocytes by interleukin-6, 48
 - interactions with in chondrocyte synthesis, 52
- Col2CTX, persistent elevation of, in type II collagen after joint injury, 167
- Collagen
- binding of
 - by noncollagenous proteins, 98
 - as a primary function of leucine-rich repeat proteins, 86
 - of cartilage, 7, 12, 87
 - fibrillar, cleavage of, 114
 - type I
 - in osteoarthritis, 21
 - in trabecular bone of osteoarthritis patients, 28
 - type II
 - cleavage of, 89–90
 - Col2CTX elevation in, after joint injury, 167

- half-life of, 99
- increased synthesis of in osteoarthritis, 97–98
- structure of, 82–85
- type III, in osteoarthritis, 20
 - interaction with type II collagen, 97
- type VI, altered distribution and organization of in osteoarthritis, 98
- type IX, in fibers, 84–85
- type X, 20–21
 - in osteoarthritis, 44, 112
- type XI, degradation of, 89
- Collagenase, *see also* Matrix metalloproteinases (MMPs)
 - 3, induction by hepatocyte growth factor, 29–30
 - cathepsin K as, 190
 - inhibitors of
 - detection from zonal differences in induced lesions, 151
 - mouse model of spontaneous osteoarthritis, 155
 - intraarticular injection of, to induce experimental osteoarthritis, 67–68
- Collagen fiber network, 84–87
- Collagen-induced rheumatoid arthritis (CIA), synergism between tumor necrosis factor and interleukin-1 in, 47
- Collagen matrix, destruction of, 72
 - evaluating inhibition of, rat model, 152
- Confocal laser microscopy, to characterize chondrocytes in living tissue, 112–113
- Connective tissue metabolism in osteoarthritis, and adipocytes, 25
- Corticosteroids, injection of, for treatment, 13
- CpG, *see* Cytosine–guanine (CpG) sites, loss of methylation in promoters of degradative enzymes
- Cross-bridge, molecular
 - with cartilage oligomeric matrix protein, 84
 - proline arginine-rich end leucine-rich repeat protein as, 86
- Crosstalk
 - between chondrocytes and extracellular matrix proteins, 114
 - between prostaglandins and nitric oxide regulating chondrocyte function, 45
 - between subchondral bone and cartilage, 28
- Cyclic stretching, responses of normal and osteoarthritic chondrocytes to, 173
- Cyclooxygenase II (Cox-2) selective inhibitors
 - induction by interleukin-1, 182
 - selective inhibitors, for pain management in osteoarthritis, 181
- Cynomolgus monkeys
 - medial tibial cartilage of, 160
 - study of long-term estrogen replacement therapy in, 25
- Cysteine proteases
 - cathepsin K, for treating osteoarthritis, 190
 - roles in tissue breakdown, 87
- Cytokines; *see also* Interleukins; Tumor necrosis factor (TNF)- α
 - anabolic and catabolic roles of, overview, v–vi, 52
 - expression of
 - increase after injury to cartilage, 167
 - in the osteoarthritic synovium, 72
 - genes for, examining for therapeutic potential, 132–133
 - inflammatory, release in osteoarthritis, 4
 - proinflammatory, and induction of anabolic factors, 102
 - role in osteoarthritis, 65
 - animal models, 48
 - sensitivity of hypertrophic chondrocytes to, 104
 - in studies using anterior cruciate ligament transection in dogs, 150
 - as therapeutic targets, 16
- Cytosine–guanine (CpG) islands, defined, 140
- Cytosine–guanine (CpG) sites, loss of methylation in promoters of degradative enzymes, 140
- Cytosol “shape”, roles in responses of cells to volume change, 117
- Decorin
 - binding of insulin-like growth factor-1 to, 50
 - fragmentation of, 91
 - responses to enzymes in vitro and in vivo, 87
 - three-dimensional structure of, 86
- Dedifferentiation., *see* Chondrocytes, dedifferentiation of
- Deep zone of cartilage, fibrils of, in the territorial matrix, 110
- Degradation, cartilage, progression in, 10, 43
- Degradative phase, of osteoarthritis, 97
- Denaturation, of collagen fibrils, due to mechanical injury, 166
- Denosumab, use to decrease bone turnover in osteoporosis, 185
- Diacerein (4,5-bis (acetyloxy)-9,10-dioxo-2-anthracene carboxylic acid), inhibition of interleukin-1 by, in vitro, 186

- Diagnosis, procedures for, 4–5
- Differentiation factors, in osteoarthritis, 49–53
- Discoidin domain receptor-2 (DDR-2), 43
- Disease modification in osteoarthritis, 182–183
- Disease modifying antirheumatoid arthritis drugs (DMARDS), 182
- Disease-modifying osteoarthritis drugs (DMOADs), 182
- DNA methylation
- defined, 140
 - loss of, and aberrant expression of degradative enzymes, 142–144
- DNA methyltransferases (Dnmts), function of, 140
- Doxycycline
- effect on collagenase and gelatinase, 189
 - for treating osteoarthritis, 191
- Drugs, disease-modifying (DMD), 14–15
- Early growth response protein (Egr-1), downregulation of, in osteoarthritis cartilage, 21
- Elastic modulus, loss of, accompanying change in bone density, 122
- Electron microscopy (EM), analyzing cartilage for apoptosis after mechanical injury with, 170
- Embryonic development disruption, and osteoarthritis, 51
- Endochondral ossification, in the degradative phase of osteoarthritis, 111
- Energy deficit, of cells in an osteoarthritic lesion, 119
- Enzyme inhibitors, in osteoarthritis synovium, 74
- Enzyme-linked immunosorbent assay (ELISA), for protein concentration changes in early osteoarthritis, 101
- Enzymes
- of the cytoplasm, as molecular machines, 116
 - degradative
 - inhibiting expression of, 14–15
 - in osteoarthritis, 10, 109
- expression of, in stage 4 osteoarthritis, 14
- synovial expression of catabolic, 73–74
- Epigenetic aspects of osteoarthritis, 131–148
- mechanisms for heritable changes in gene function without mutations of DNA, 11
- Estrogen receptor α gene (*ESR1*), targeting for study, 132
- early report, 133
- Estrogen therapy, effect on bone marrow lesions in osteoarthritis, 184
- European League Against Rheumatism (EULAR) responses, 189
- Evaluation of the Chondro modulating effect of Diacerein in osteoarthritis of the Hips (ECHODIAH), 186
- Extracellular matrix (ECM)
- of cartilage, 6–8, 81
 - response to mechanical injury, 171
 - structural proteins of, targeting genes coding for, 132–133
- Family studies of osteoarthritis, 131–132
- Femoral cartilage, degenerative changes after partial medial meniscectomy, 150
- Fibrils, collagen, assembly of, 84
- Fibroblast growth factor (FGF)
- FGF-2, binding to heparan sulfate chains, 81
 - FGF-18
 - for cartilage repair in a rat model, 152
 - promotion of cartilage repair by, 49
- effect of bisphosphonates on, 192
- patterning and cell proliferation coordination by, 51
- Fibroblasts
- communication with synovial macrophages, 69
 - synovial, expression of CD44 by, 74
- Fibromodulin
- cleavage by matrix metalloprotein-13, 87
 - fragmentation of, 88–91
- Fibronectin
- accumulation in osteoarthritis cartilage, 97
 - early stage, 101
 - increase in expression of, in osteoarthritic cartilage, 112, 173
 - increase in synthesis of, after mechanical compression injury, 170
 - interactions and fibril formation, 86
 - interaction with cartilage oligomeric matrix protein, 84
 - release from the extracellular matrix, effect on rate of breakdown of the matrix, 81
- Final strain, defining injurious joint loading in terms of, 169
- Follistatin, association with inflammatory processes, 52
- Framingham Study, evaluation of radiographic hand osteoarthritis in families in, 135
- Frizzled-related protein (FRP)
- 3, gene for, and cartilage development, 2

- secreted, role in chondrocyte apoptosis in osteoarthritis, 53
- Gelatinases, *see* Matrix metalloproteinases (MMPs)
- Gender, and prevalence of osteoarthritis, 24–26
- Genes
- ADAM12*, encoding a metalloproteinase, 144
 - ADAMTS-5*, prevention of osteoarthritis by deletion of, 114
 - Ank*, mutation related to early-onset osteoarthritis, 54
 - for asporin
 - association with hip and knee osteoarthritis, 144
 - polymorphisms in, 53
 - associated with osteoarthritis, evidence from linkage scans, 134
 - calmodulin 1 (*Calm1*), association with hip osteoarthritis, 139
 - cancer-inducing, loss of methylation leading to activation of, 141
 - chondrocyte
 - DNA hypermethylation of, 142
 - effects of cartilage injury on expression of, 171
 - COL10A1*, encoding collagen type X, 44
 - COL2A1*, encoding a polypeptide chain of collagen type II, 132
 - collagen, mutations of, 2
 - developmental, reexpression in osteoarthritis cartilage, 15
 - enhanced and altered expression of in osteoarthritis, 97
 - ESR1*, association with osteoarthritis in females, 132
 - estrogen α -receptor, involvement in osteoarthritis, 24–25
 - frizzled-related protein (*FRZB*)
 - association with hip osteoarthritis in females, 146
 - polymorphisms in, 53
 - for hand or hip osteoarthritis, 45
 - IL1* cluster, osteoarthritis phenotypes associated with, 133–134
 - for interleukin-1B, susceptibility to osteoarthritis in the absence of, 103
 - leucine-rich repeat and calponin homology containing, 139
 - MATN3*
 - association with osteoarthritic cartilage, 135
 - association with spine osteoarthritis, 136
 - matrix gene expression in cartilage, regulation of, 52
 - methylation for X chromosome inactivation, 140
 - obese (*ob*), 22
 - predisposing, overview, vii, 133
 - silencing by DNA methylation in the regulatory regions, 11–12
 - silent, expression due to random loss of methylation, 141
- Gene therapeutic approaches, 188
- targeting the osteoarthritis synovium, 76–77
- Genetic aspects of osteoarthritis, 131–144
- Gene transfer, models of, 14
- Genome-wide association scans, 139–140
- Genome-wide scans, 133–134
- Gibbs-Donnan relationship, for disequilibrium of charged particles within cells and the extracellular fluid, 115
- Glucose Arthritis Intervention Trial (GAIT), controlled trial evaluating chondroitin sulfate and glucosamine hydrochloride, 181
- Glucose transporter proteins (GLUTs), in chondrocytes, 42
- Glycolysis, role in autophagy induction, 121
- Glycosaminoglycan (GAG)
- sulfated (sGAG)
 - release after joint injury, 166
 - and stiffness of cartilage, 166
 - synthesis of
 - by chondrocytes, 41
 - effects of deformation of the rough endoplasmic reticulum on, 172
- Gremlin, association with hypertrophic phenotype in osteoarthritis cartilage, 52
- Growth factors; *see also* Fibroblast growth factor (FGF); Hepatocyte growth factor (HGF), role in cartilage degradation; Insulin-like growth factors (IGFs); Transforming growth factor (TGF); Vascular endothelial growth factors (VEGFs)
- heparin-binding, role in chondrogenesis, 8
 - in osteoarthritis, 49–53
 - potential for therapy using, 73
 - release in matrix degradation, 81
- Growth plate
- development of, genes associated with, 44
 - terminal differentiation of cells of, 112
 - and chondrocyte function in osteoarthritis, 124

- Hand osteoarthritis, risk of
 - identifying chromosome loci associated with, 136
 - to siblings of hip replacement probands, 132
- Heberden's nodes, 3
- Hepatocyte growth factor (HGF), role in cartilage degradation, 29–30
- Heritability, of genes altered by methylation changes, 139–140
- Heritable changes, in chondrocytes in osteoarthritis, 11
- Hip replacement, study of pedigrees of individuals having, 132–134
- Homeostasis, cartilage, mediators of, 52–53
- Human osteoarthritis, bisphosphonate treatment with, 184
- Hyalin cartilage, vascularization of, 23
- Hyaluronan, binding to aggrecan, 83, 88
- Hyaluronan receptor CD44, 74
- Hyaluronic acid
 - interaction with aggrecan, 98
 - intraarticular injection of, for treating knee osteoarthritis, 13
- Hydration, in degenerative and nondegenerative cartilage, 115
- Hydroxyapatite crystallites, in the base of articular cartilage, 110
- Hyperanabolism
 - causes of, 101
 - osteoarthritis, significance in disease progression, 97–98
- Hypermethylation, leading to tumor cell growth, 141
- Hypertrophy
 - of cartilage, in a dog model using anterior cruciate ligament transection, 151–152
 - cellular, effect on the osmotic pressure of the extracellular matrix, 114–115
 - of chondrocytes
 - in the biosynthetic phase of osteoarthritis, 111
 - as a target in drug development for osteoarthritis, 122
 - defined, 110–111
- Hypoxia, role of, in osteoarthritis, 20–21
- Hypoxia inducible factor-1 α (HIF-1 α)
 - upregulation by chondrocytes in response to low oxygen tension, 42
 - upregulation in catabolic stress, 52
- Iliac crest bone, growth factor levels in, in osteoarthritis patients, 27
- Imprinting, with methylation, 140
- Index Chemicus Registry System (ICRS), scale for stiffness of cartilage, 166
- Inducible nitric oxide synthase (iNOS)
 - in apoptosis pathways, 109
 - role in pathogenesis of osteoarthritis, 120–121
- Inflammation, in osteoarthritis pathogenesis, 43–44
- Insulin-like growth factors (IGFs)
 - 1
 - effects on articular chondrocytes, 101–102
 - levels of, in iliac crest bone, of patients with osteoarthritis, 22
 - levels of, in osteoblasts of osteoarthritis patients, 27, 29
 - maintenance of the chondrocyte phenotype by, 50
 - 2, levels of, in iliac crest bone of patients with osteoarthritis, 22
- Integrins
 - as fibronectin fragment receptors, 48
 - receptors for, expression patterns in osteoarthritic cartilage, 175
- Interleukin-1 antagonists, as potential treatments for osteoarthritis, 187–188
- Interleukin-1 β converting enzyme (ICE), 187
 - effect on knee osteoarthritis in mice, 48
 - inhibitor of
 - evaluation as a treatment for osteoarthritis, 187
 - for managing osteoarthritis, 72
- Interleukin-1 receptor
 - monoclonal antibody binding to, evaluation for osteoarthritis treatment, 187
 - type II (IL-1R type II), (“decoy receptor”), 185
- Interleukin-1 receptor antagonist (IL-1RA), 48
 - gene transfer of, 14
 - potential for therapy in osteoarthritis, 185
- Interleukin inhibitors, IL-1RN, targeting for genetic study, 133
- Interleukins
 - IL-1
 - cartilage degradation by, 87
 - contributions to loss of and to synthesis of cartilage matrix, 55
 - destruction of articular cartilage associated with, 44–45
 - destruction of the cartilage network by reactions involving, 75
 - gene therapy targeting, 75
 - receptor antagonist, inhibition of chondrocyte catabolism with injection of, 48

- release of fibromodulin from cartilage by, 87
as a therapeutic target, 185–187
- IL-1 β
acceleration of osteoarthritis in mice by, 45
increase in levels of, after mechanical joint injury with inflammation, 166
modulation of extracellular matrix turnover by, 30
targeting for genetic study, 131–132
- IL-4, role in maintenance of cartilage integrity, 70
- IL-6
enhancement of tissue inhibitors of metalloproteinases by, 73
modulation of extracellular matrix turnover by, 30
roles of, 46–47
- IL-17
induction of catabolic responses in chondrocytes, 49
production of, in the synovium in osteoarthritis, 70
- IL-18
mediation of autoimmune processes in inflammation models, 49
production of, in the synovium in osteoarthritis, 70
- Interterritorial collagen network, composition of, 41
- Interterritorial matrix
fibrils of, 110
molecules in, 81
- Intraarticular iodoacetate injection, in a rat model of osteoarthritis, 153–154
- Ischemia reperfusion injury, similarity to nutritional changes in hypertrophy, 122
- Joint capsule tissue, co-culture with injured cartilage, 173
- Joints; *see also* Knee
loading of, changes with osteoarthritis, 166
macroscopic changes in, 3
mechanical aspects of functions, overview, vii–viii
space narrowing in, as a measure of osteoarthritis progression, 182
- Knee
gene locus associated with osteoarthritis susceptibility of, 132
subchondral bone sclerosis associated with cartilage destruction in, 19
- Knee osteoarthritis, association with the leucine-rich repeat and calponin homology containing 1 (*LRCH1*) gene, 139
- Knee replacement, risk of osteoarthritis in siblings of probands, 134
- Lactic acid, increase in osmotic pressure due to, 116
- Latent transforming growth factor (TGF)- β binding protein (LTBP), matrix proteins binding, 77
- Leptin, vi
expression of, and cartilage degradation, 103
level of, in osteoarthritic cartilage and osteophytes, 53
and metabolism of subchondral bone osteoblasts, 25
stimulation of differentiation of mesenchymal cells into osteoblasts by, 28
- Lesions
in a dog model of experimental osteoarthritis, zonal evaluation of, 151
in a guinea pig model of experimental osteoarthritis, 155–159
in a rabbit model of experimental osteoarthritis, 183
in a rat model of experimental osteoarthritis, 155
- Leucine-rich repeat (LRR) proteins, 85–86
retention during fibromodulin fragmentation by interleukin-1, 88–89
- Leucine-rich repeat and calponin homology containing 1 (*LRCH1*) gene, association with knee osteoarthritis, 139
- Leukotriene (LT)
B₄, modulation of extracellular matrix turnover by, 28
stimulation of, by leptin, 22
- Linkage scans, 134–136
- Loading, abnormal, and risk of osteoarthritis, 2
- LOD (logarithm of the odds to the base 10) scores, as a measure of the likelihood two chromosomal loci are inherited together, 133
- Loose bodies, locking of joints due to, 3
- Lysyl oxidase, role in crosslink formation in collagen fibers, 84, 100
- Macrophages
activation of, interactions in osteoarthritis, 81

- synovial
 - association with cartilage changes in experimental osteoarthritis, 69
 - depletion of experimentally, 68
 - growth factor from and osteophyte formation, 67–68
 - production of interleukin-1 by, 71
- synovial lining
 - mediation of osteophyte formation by, 54, 102
 - in rheumatoid arthritis and osteoarthritis, 66
- Magnetic resonance imaging (MRI)
 - to assess structural changes affecting cartilage, soft tissues, and bone, 21
 - to discriminate between osteoarthritic and nonarthritic pain, 5
- Mankin grading scale
 - for cartilage degradation in osteoarthritis, 8–10
 - for defining severity of osteoarthritis, 12
- Matrilins
 - 3, gene for, association with hand osteoarthritis, 134–136
 - extracellular matrix molecules involving, 84
- Matrix; *see also* Cartilage oligomeric matrix protein (COMP); Extracellular matrix (ECM); Pericellular matrix
 - composition of
 - during osteoarthritis, 8
 - role in osteoarthritis, overview, macromolecules of, influence on cell hypertrophy, 113–114
- Matrix metalloproteinases (MMPs)
 - activity increase in cancellous bone, 23
 - chondrocyte synthesis of, and interleukin-1 and tumor necrosis factor- α , 46
 - cleavage by
 - of biglycan, 91
 - of fibrillar collagen, 91–92
 - of releasing transforming growth factor- β , 81
 - expression in the osteoarthritis synovium, 73–74
 - increase in cancellous bone activity on the osteoarthritic hip, 22
 - inhibition of, by bisphosphonates, 183
 - inhibitors of, for treating osteoarthritis, 191
 - production by fibroblasts in the synovium, 71
 - VDIPEN neoepitope as an indicator for activity of, 70–71
 - VDIPEN-3
 - increase in , after joint injury, 165
 - involvement in matrix degradation, 10
- VDIPEN-9, methylation status of promoters of, in osteoarthritis, 140
- VDIPEN-13
 - cleavage of fibromodulin by, 88–89
 - in the guinea pig model of osteoarthritis, 164
 - in the rat model of osteoarthritis, 153
 - in the synovium and cartilage of osteoarthritis patients, 73
- Maxwellian switches, of the cytosol, modulate macromolecule complex formation dissociation and function, 116
- Mechanical injury
 - association with osteoarthritis, 165
 - to the joint, in vitro models of injury and cytokine treatment, 173
 - mechanoresponsiveness of chondrocytes after, 172–173
- Mechanical properties
 - of articular cartilage, 5
 - disturbance of, and thinning of the articular cartilage, 27
 - of osteoarthritic cartilage, 173
- Mechanical stress
 - modulation of chondrocyte energy requirements by, 41
 - release of fibroblast growth factor-2 in response to, 49
 - on weight-bearing joints, and microfractures in the bone plate, 24
- Medial collateral ligament transection
 - in a mouse model of osteoarthritis, 155
 - in a rat model of osteoarthritis, 152
- Medial meniscal tear
 - in a guinea pig model of osteoarthritis, 157–159
 - in a rat model of osteoarthritis, 152
- Medial meniscectomy, partial
 - in a dog model of osteoarthritis, 150–153
 - in a rabbit model of osteoarthritis, 159–160
- Medial tibial cartilage, of a cynomolgus monkey, 157
- Medications, overview, viii, 196
- Membrane potential, decrease in, and autophagy, 120
- Membrane transport, active, to exchange cations, 42
- Meniscal tears, injuries to, and relative risk of osteoarthritis, 165
- Meniscectomy, to induce osteoarthritis in rabbits, 156–159
- Mesenchymal cells, involvement in chondrogenesis, 68, 104

- Mesenchymal stem cells (MSCs)
 activity of cells derived from, and osteoarthritis, 25
 adipocytes derived from, and connective tissue metabolism in osteoarthritis, 27
- Messenger RNA (mRNA)
 collagen type II, comparison between osteoarthritic and normal cartilage, 97–98
 expression in chondrocytes in cartilage, 21
 MMP-13, levels in synovium and cartilage in experimental osteoarthritis, 73
 Sox9, decreased levels of near osteoarthritic lesions, 45
- Metabolism, changes linked to induction of hypertrophy and apoptosis in osteoarthritis, 120
- Microscopic changes
 in articular cartilage, 8–10
 and bone stiffness, 26
- Microscopic evaluation, of induced lesions in the dog, 149
- Mineralization, of osteoid matrix in generalized bone disease, 27
- Minocycline in Rheumatoid Arthritis (MIRA) study, 189
- Mitochondrial transmembrane potential, decrease in response to apoptosis, 109
- Mitochondrion, role in apoptosis by, 117–118
- Mitogen-activated protein kinase (MAPK), activation of signaling in response to mechanical injury, 172
- Mitogenesis, in chondrocytes, roles of fibroblast growth factors and inhibitors in, 51
- Molecular nanomechanics, and chondrocyte response, 175
- Monoclonal antibodies, potential therapy using, 186
- Morphology
 of chondrocytes, 109–115, 116
 normal, of the synovium, 65–66
- Motion, changes in range of, with progressing disease, 2
- MRNA., *see* Messenger RNA (mRNA)
- MTOR., *see* Rapamycin (mTOR)
- Muckle-Wells syndrome, treating with anakinra, 187
- Necrosis, defined, 12
- Neopeptides
 Col2CTx, elevation of, in type II collagen after joint injury, 167
 VIDIPEN, as an indicator of matrix metalloproteinase activity, 70
- Nitric oxide (NO)
 crosstalk with prostaglandins, to regulate chondrocyte function, 47
 generation due to electron transport disturbance, 120
 upregulation of production by interleukin-1 and tumor necrosis factor- α , 47
- Noncollagenous collagen-binding proteins, 84–92
 fragmentation of, 89–91
- Nonpharmacologic interventions, in osteoarthritis, 181
- Nonsteroidal antiinflammatory drug (NSAID), reduction in subchondral bone remodeling and resorption reduced by, 26
- Nonsteroidal antiinflammatory drugs (NSAIDs), to managing pain in osteoarthritis, 181
- Non-weight bearing regions, stage 2 osteoarthritis cellular changes involving, 11
- Nuclear factor- κ B (NF κ B)
 activation of bone morphogenetic protein-2 transcription by, 50
 small molecule inhibitors of, effect in rheumatoid arthritis, 47
- Nuclear structure, effect of mechanical injury on molecular transport through, 172
- Nucleotide pyrophosphatase
 phosphodiesterase-1 (Npp-1), early onset osteoarthritis associated with knockout of, 54
- Nutriceuticals
 for pain management in osteoarthritis, 181
 to slow osteoarthritis progression, 26
- Nutrition
 of articular cartilage, 20–21
 of cartilage zones, 98
- Nutritional deprivation, link to cell cycle arrest and activation of apoptosis, 120
- Obesity
 and rate of osteoarthritis progression, 26
 risks of
 abnormal loading, 2
 arthritic knees, in guinea pigs, 157
 osteoarthritis, 24–25
- Occupation, as a risk factor for abnormal loading, 2
- Omega-3 fatty acids, inhibition of degradative enzymes by, 14–15

- Oncostatin M (OSM)
synergism with interleukin-1 in cartilage breakdown, 87–89
synergism with interleukin-1 or tumor necrosis factor- α , 46
- Osmolytes, synthesis by chondrocytes, 116
- Osmometers, chondrocytes as, 115
- Osmotic pressure
chondrocyte adaptation to changes in, 115–117
of cytosol, depletion of cell nutrients due to, 120, 122
of the extracellular matrix
and cell hypertrophy, 113–114
regulation by charged groups of proteoglycan, 114
- Osteoarthritis (OA), defined, 1, 41
- Osteoarthritis Research Society International (OARSI), 191
grading system for histopathologic changes in osteoarthritis, 8
- Osteoblasts
arthritic, PGE₂ and leukotriene B₄ levels in, 22
cells derived from, and osteoarthritis, 25
metabolic rate of, in osteoarthritis patients, 28
role of, in abnormal bone tissue metabolism in osteoarthritis, 22
subchondral, phenotypic differences in early osteoarthritis, 19
transforming growth factor- β role in inducing activity of, 104
- Osteocalcin, synovial fluid
to assess bone formation, 22
to assess bone formation in knees, 27
- Osteochondrodysplasia
mutation of genes in, 131
osteoarthritis accompanying, 131
- Osteochondrosis, from anterior cruciate ligament transection in immature rats, 153
- Osteoclasts
differentiation of macrophages in the synovial membrane into, 23
effects of bisphosphonates on, 183
- Osteoid collagen matrix, increase in undermineralized osteoid collagen matrix, 19
- Osteophytes, formation of, 24, 104
in a rat model, 152
- Osteophytes, in joints, effect on movement range, 3
- Osteophytosis, severe, in a dog model using anterior cruciate ligament transection, 151
- Osteopontin
increase in expression of, in osteoarthritic cartilage, 173
levels of, after trauma, 22
- Osteoporosis, relationship with osteoarthritis, 1, 183
- Osteoprotegerin (OPG), effect of bisphosphonates on, 183
- Osteotomy, to prevent osteoarthritis, by correcting bony malalignment, 13
- Outcome Measures in Rheumatology Clinical Trials (OMERACT), 188, 191
- Outerbridge classification, of chondral damage, 5
- Overexercise, as a risk factor for osteoarthritis, 24
- Oxygen supply, to chondrocytes, 20
- P38 kinases
role in differentiation of chondrocytes, 51
stress-activated, signal transduction by, 47
- Paget's disease, calcitonin for treating, 185
- Pain
bone-related, in osteoarthritis, 181
progressive, in osteoarthritis, 2–3
role of interleukin-1 in, 185
- Papain, attack on cartilage by, 87
- Parathyroid hormone (PTH), resistance to, 22
- Pathogenesis
of knee osteoarthritis, in guinea pigs, 157
of osteoarthritis, 1–14
roles of reactive oxygen and nitrogen species, 120
- Pathology
cartilage, roles of cytokines in the synovium, 72
pathobiology of osteoarthritis, 5
pathophysiology of osteoarthritis, v, 182
- Peak stress, defining injurious joint loading in terms of, 168
- Pericellular matrix
biglycan of, 75
composition of, 42
deformations of, effect on transport of soluble factors to cell-surface receptors, 172
- Perlecan
binding of fibroblast growth factor-2 to, 81
role in chondrogenesis, 8
- Peroxisome proliferators-activated receptor γ (PPAR γ), agonists to, protecting chondrocytes against IGF response, 50–51

- Peroxynitrite (ONOO⁻), formation from nitric oxide and reactive oxygen species, 120
- Phenotype, alteration of, as a mechanism for anabolic failure of chondrocytes, 21
- Placebo benefit
in the glucose arthritis intervention trial, 181
in the Minocycline in Rheumatoid Arthritis study, 189
- Polymerase chain reaction, to identify changes in gene expression after mechanical injury, 171
- Polymorphonuclear neutrophils (PMNs), presence in rheumatoid arthritis in the synovium, 67
- Polyunsaturated fatty acids (PUFAs), modulation of the inflammatory process by, 29
- Pralnacasan, interleukin-1 β -converting enzyme inhibitor, reduction of joint damage with, 48, 187
- Prevalence of osteoarthritis, 24–26
- Primate models, of osteoarthritis, 160
- Progression of articular disease, 182
association with symptom relief, 188
- Proline arginine-rich end leucine-rich repeat protein (PRELP), interaction with heparin and heparan sulfate, 86
- Proline arginine-rich protein (PARP), release of, in collagen XI degradation, 91
- Prostaglandins
crosstalk with nitric oxide, to regulate chondrocyte function, 47
- E₂
modulation of extracellular matrix turnover by, 28
stimulation of, by leptin, 48
upregulation of production by interleukin-1 and tumor necrosis factor- α , 46
- Prostheses, managing damaged bone before inserting, 3, 14
- Proteases, *see also* Matrix metalloproteinases (MMPs)
cysteine
roles in tissue breakdown, 87
for treating osteoarthritis, 187
increased production of, and cartilage damage, 43
response of, in joint injury, 170
serine, upregulation of HtrA1 by, in osteoarthritis, 87
special, to degrade collagen triple helices, 81
synthesis of, induction by interleukin-1 and tumor necrosis factor- α , 46
- Proteinases, *see* Proteases
- Proteoglycan loss
detection of, from zonal differences in iodoacetate induced lesions, 151, 153
from mechanically injured bovine knee cartilage explants, 173
in stage 2 osteoarthritis, 11
- Proteoglycans
in articular chondrocytes, p38 activity in synthesis of, 50, 101
Bcl-2 role in regulating synthesis of, 118–119
in cartilage, 7
assessing with magnetic resonance imaging, 182
changes in expression of, 69
changes in expression of, after mechanical injury, 171, 173
imbalance of components in osteoarthritis, 100
synthesis of in early osteoarthritis, 101
synthesis of in osteoarthritis, 97
heparan sulfate, role in chondrogenesis, 8, 84
synthesis of, after mechanical compression injury, 170
- Proteomic approaches to biomarkers of joint injury and osteoarthritis, 174
- Pump proteins, as a target for drug development to manage osteoarthritis, 124
- Rabbit models, of osteoarthritis, 159, 188
- Racemization in collagen, alteration in osteoarthritis, 99
- Radiographic scale, Kellgren and Lawrence, for evaluating osteoarthritis, 4
- Radiography, for diagnosing osteoarthritis, 4–21
- Rapamycin (mTOR)
regulation of autophagy by, 107, 121–122
sensitivity to the osmotic status of a cell, 117
- Rate of loading, defining injurious joint loading in terms of, 169
- Rat models, of osteoarthritis, 152
- Reactive oxygen species (O), in deregulated mitochondrial metabolism, 120, 122
- Receptor activation of nuclear factor- κ B ligand (RANKL), mediation of osteoclast differentiation and activity by, 53
- Receptor for advanced glycation end products (RAGE), 74, 76
of chondrocytes, and expression in synovial tissue of osteoarthritis patients, 76

- Regulated on Activation Normal T-cell Expressed and Secreted (RANTES), expression of receptors for, in osteoarthritis, 43, 49, 74
- Regulatory cytokines, inhibition of catabolic enzyme production by, 72
- Relacatib, study of, as a treatment for osteoarthritis and osteoporosis, 190
- Repair response, osteophyte formation as, 26
- Rheumatoid arthritis
evaluating progression in, 181
gene therapy for, evaluation of interleukin-1 receptor antagonist, 48
synovium in, comparison with osteoarthritis synovium, 65–66
- Riloncept (IL-1-Trap), 187
- Risedronate
clinical trials of, 184, 187
effects on osteoarthritis progression
animal models, 183, 186
human trial, 184
- Risk factors
for abnormal loading, occupational, 24
for osteoarthritis, 161, 181
reducing, 13, 50
- Scales
Kellgren and Lawrence
correlation with bone loss, 21–22
radiographic scale, 4
Mankin, for cartilage degradation in osteoarthritis, 8–12
Outerbridge, for chondral damage, 5
- Sectioning, to maintain zonal relationships in evaluating animal models, 151
- Selection of an animal model, 149, 160
- Serine proteases, upregulation of HtrA1 in osteoarthritis, 87
- Shear resistance, of collagen, 166
- Side effects
of Diacerein, 186
of matrix metalloproteinase inhibitors, 190
of minocycline, 189
of pralnacasan, hepatotoxicity, 187
- Signaling pathways
induction by growth and differentiation factors, 49–51
JAK/STAT, role of interleukin-6 in, 48, 52
regulation by cytokines, 46–47
- Somatomedin C., *see* Insulin-like growth factors (IGFs), -1, Index, p.207
- Spontaneous osteoarthritis
in animal models
guinea pigs, 157–158
mice, 155–156
resemblance of animal models to human osteoarthritis, 160
- Spontaneous osteoarthritis, in animal models, dogs, 160, 170
- Stages, of cellular change in osteoarthritis, 10–19
- Stiffness
bone
and cartilage integrity, 27
and origination of osteoarthritis, 24–26
compressive, contribution of aggrecan to, 166
- Stress response
links with autophagy, 122
links with caspase level increase and mitochondrial dysfunction, 120
- Stromal cell-derived factor 1 (SDF-1), ligand for CXCR4, levels in synovial fluids in rheumatoid arthritis and osteoarthritis, 49, 66
- Stromelysin, *see* Matrix metalloproteinases (MMPs), -3
- STR/ort model, of arthritis in mice, 155
- Structure-function relationship, in articular cartilage, 6
- Structure-modifying osteoarthritis drugs (SMOADs), 182
- Subchondral bone
and articular cartilage, crosstalk between, 21, 29–30
changes in a rat model using iodoacetate injection, 153
factors associated with dysfunctional chondrocyte responses in osteoarthritis, 53
femoral, thickening of, in induced experimental lesions, 150
role of, v, 5–8
source of nutrients for articular cartilage, 28
structural changes in, with disease progression, 26, 151
turnover of, in osteoarthritis, 28
- Subchondral cortical plate, thickening of, as an early change in osteoarthritic joints, 21, 122
- Subluxation, and risk of osteoarthritis, 2
- Superficial zone of cartilage, fibrils of, 20
- Suppression of cytokine signaling-3 (SOCS3), 50, 52
inhibition of insulin-like growth factor-1 signaling by, 49, 50
- Surgical interventions, 13
- Surgically induced models of osteoarthritis, rate of change in, 160

- Synovial fluid
 levels of matrix metalloproteinase-3 after injurious joint loading, 166–167
 as a source of nutrients for articular cartilage, 28–29, 75, 110
- Synovial membrane, and inflammation, 6
- Synoviocytes
 type A, mediation of tissue damage and inflammation by, 65, 66, 104
 type B, production of hyaluronan by, 65, 66
- Synovitis, in advanced osteoarthritis, 45
- Synovium
 enzymes originating in, in osteoarthritis, 10
 inflammation of, from adenoviral overexpression of oncostatin M, 48
 role in osteoarthritis, 65
 overview, vi
- T cells, interleukin-4 of, in osteoarthritis patients, 28
- Tensile resistance, of collagen, 166
- Tensile strength, loss of, in the cartilage matrix, 97
- Terminal deoxynucleotidyl Transferase Biotin-dutp Nick End Labeling (TUNEL) staining
 demonstrating induction of apoptosis by mechanical injury, 170
 identification of apoptotic cells with, 111, 118
- Territorial molecules in the cartilage extracellular matrix, 117
- Tetracyclines, inhibition of collagenases by, 189
- Threshold levels, of strain rate or peak stress, and tissue damage, 169
- Thrombospondins, 84, 85; *see also* Cartilage oligomeric matrix protein (COMP)
- Tibial cartilage, degenerative changes after partial medial meniscectomy, 153
- Tidemark
 defined, 112
 in osteoarthritic cartilage calcified zone, 118
- Tissue engineering, use of bone morphogenetic proteins in, 45, 51
- Tissue inhibitor of metalloproteinases (TIMPs)
 TIMP-1, expression of, after injury to cartilage, 167, 169
 increase induced by interleukin-6, 48
 presence in arthritis, 188, 189
 in the synovial fluid of osteoarthritis patients, 74
- Toll-like receptors (TLRs), synovial, in rheumatoid arthritis and osteoarthritis, 74, 75
- Total hip replacement (THR), risk of osteoarthritis to siblings of probands, 14, 132
- Trabecular bone
 features of in osteoarthritis pathogenesis, 53
 subchondral, characterizing, 5, 22
- Transcription factors, increase in expression of, after injury to cartilage, 104, 141, 171
- Transforming growth factor (TGF)
 $-\beta$
 induction of osteophytes by, 67
 levels in patients with osteoarthritis, 22
 loss of signaling by, and pathology in articular cartilage, 54
 protection against cartilage injury by, 171
 response of osteoarthritis tissue to, 100
 signal transduction by, 47
 stimulation of aggrecan synthesis by, 43
 stimulation of matrix synthesis and collagenase activity by, 28
- $-\beta 1$
 gene as a target for studying osteoarthritis, 132
 role in expression of collagen type IIA, 20
- Trauma, as a risk factor for osteoarthritis, 24, 42
- Treatment
 for alleviating pain and reducing inflammation, 13
 animal models, 48, 149, 183
 with bisphosphonate for human osteoarthritis, 183, 184,
 corticosteroid injections, 13
 intraarticular, evaluating in experimental dogs, 153
 novel therapeutics for osteoarthritis, 181–191
 for rheumatoid arthritis with anakinra, 187–188
- Triple helix, of collagen, 84
- Tumor necrosis factor (TNF)- α
 increase in levels of, after mechanical joint injury with inflammation, 166
 production of, in the synovium in osteoarthritis, 70–71
 sensitivity of osteoarthritis chondrocytes to, 29, 49
 suppression of cartilage anabolism by, 52
- Tumor necrosis factor receptor (sTNFR), soluble, increase induced by interleukin-6, 53

- Twin studies, of osteoarthritis risk, 131, 132
- Urokinase-type plasminogen activator (uPA), in bone remodeling and resorption effects of nonsteroidal antiinflammatory drugs, 13, 26, 181
- Van't Hoff equation, expressing colloid pressure change with glycolysis, 123
- Vascular channels
from the subchondral bone to articular cartilage, 34
in the deep calcified cartilage zone, 111
- Vascular endothelial growth factors (VEGFs)
effect of bisphosphonates on, 192
production of, in articular cartilage, 30
role in angiogenesis and, 52
- Vascularity
of bone, role in the pathogenesis of osteoarthritis, 109
local, and joint tissue integrity, 23
role in the pathogenesis of osteoarthritis, 120
- Versican (proteoglycan-M), expression of, in limb buds and in osteoarthritis, 21
- Vioxx (rofecoxib), effects leading to market withdrawal, 13
- Vitamin A, subchondral bone proliferation promoted by derivatives of, 29
- Vitamin D receptor gene (*VDR*), targeting for study
reports of association with knee osteoarthritis, 133
- Von Willebrand factor A domains of matrilin, 86
- Water, of cartilage, 22, 72
- Western Ontario McMaster University
Osteoarthritis (WOMAC) index, 187
- Wolff's law, 5